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Abstract
Background: Monitoring of plasma drug levels is manda-
tory in patients receiving high-dose methotrexate. This 
study evaluated the analytical performance of the novel 
Architect and the established ARK™ methotrexate immu-
noassay (running on the Roche Cobas© c502 analyzer) in 
comparison with liquid chromatography-mass spectrom-
etry (LC-MS) and the TDx/TDxFLx Methotrexate II assay.
Methods: Imprecision and linearity were verified for 
the Architect and ARK assay according to CLSI EP15-A3 
and EP6-A guidelines, respectively. The reported limit 
of  quantitation (0.04 μmol/L) was tested for both assays 
according to the CLSI EP17-A2 guideline. Correlation and 
agreement between the different assays were evaluated 
using residual plasma samples (n = 153).
Results: Total imprecision was  < 6.3% and  < 9.5% for the 
Architect and ARK assay, respectively. The claimed linear-
ity and limit of quantitation were confirmed for the Archi-
tect assay. For the ARK assay, imprecision at the limit of 
quantitation was  < 18% with a positive bias resulting in a 
high total error up to 58%, and hence the linearity could 
not be confirmed. Both assays showed strong correla-
tions with the TDX assay and LC-MS but a positive bias of 
12.2% and 20.5% in comparison to LC-MS for the Architect 
and ARK assay, respectively. For the ARK assay this bias 
increased dramatically for samples with concentrations 
towards the limit of quantitation.
Conclusions: The Architect assay is suitable for moni-
toring plasma methotrexate, but the ARK assay showed 
unsatisfactory performance in the analysis of low concen-
trated samples. Unlike the TDX assay, both assays require 
manual dilution of samples at higher concentrations, 
which delays sample processing in clinical routine.
Keywords: high dose methotrexate; liquid chromatogra-
phy mass spectrometry; immunoassay; method valida-
tion; therapeutic drug monitoring.
Introduction
Methotrexate (MTX) is a folate antagonist used at high 
dosage (HDMTX) in the treatment of a variety of malignant 
diseases, including leukemia, lymphoma and osteosar-
coma. However, HDMTX is nephrotoxic due to precipita-
tion of the drug in the kidney. This adverse effect can be 
counteracted by hydration and urine alkalization. In the 
HDMTX regimen, a lethal dose of MTX ( ≥  500 mg/m2) is 
administered by infusion over 4–36 h, and MTX toxicity is 
reduced by “rescue” with reduced folates (leucovorin or 
folinic acid) 24–36 h after the start of treatment.
Therapeutic drug monitoring (TDM) is used to guide 
timing, dosage and continuation of leucovorin rescue to 
prevent excessive toxicity during HDMTX treatment: if 
plasma MTX concentrations exceed 5–10 μmol/L at 24 h, 
0.9–1 μmol/L at 48  h or 0.1 μmol/L at 72 h, leucovorin 
dosing and intravenous hydration must be increased to 
prevent severe toxicity [1, 2]. If MTX clearance is severely 
compromized and plasma MTX levels grossly exceed these 
limits, administration of glucarpidase (carboxypeptidase 
G2, Voraxaze®), which cleaves MTX to the inactive metab-
olite 2,4-diamino-N-methylpteroic acid (DAMPA), can 
rapidly lower circulating MTX levels.
Current methods for the measurement of MTX 
include enzymatic and immunological assays as well as 
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chromatographic techniques [3]. However, the partially 
active metabolite 7-hydroxymethotrexate (7-OHMTX) or 
DAMPA can strongly interfere with immunoassays [4, 5], 
and the high cross-reactivity with DAMPA limits the use of 
immunoassays to monitor glucarpidase rescue. In our lab-
oratory, MTX has been measured by means of the Abbott 
TDx/TDxFLx methotrexate II assay for more than 20 years, 
but in 2014 this assay was replaced by the manufacturer 
with a chemiluminescence microparticle immunoassay 
(CMIA) running on Abbott Architect immunoassay plat-
forms. The aim of this study was to evaluate the analyti-
cal performance of both the novel Architect methotrexate 
assay and the established ARK™ methotrexate assay 
running on the Roche Cobas® c502 analyzer, which is 
 distributed as a Roche partner channel reagent since 2014, 
in comparison with the former TDX assay and a liquid 
chromatography-mass spectrometry (LC-MS) method.
Materials and methods
LC-MS analysis
MTX and the internal standard methotrexate-d3 were purchased 
from Cerilliant (Round Rock, TX, USA) and 7-OHMTX from TRC (ON, 
USA). Ammonium acetate was purchased from Scharlau (Taegerig, 
Switzerland), formic acid and acetone from Merck ( Darmstadt, 
 Germany), methanol and 2-propanol from Honeywell Seelze (Seelze, 
Germany) and acetonitrile from Romil (Cambridge, UK). All solvents 
and reagents were of high performance liquid chromatography 
(HPLC) grade.
Standard samples, prepared by adding specified amounts of 
MTX (0.01, 0.06, 0.22, 1.10, 2.20, 5.51, 11.01 μmol/L) and 7-OHMTX 
(0.01, 0.05, 0.21, 1.06, 2.13, 5.32 and 10.64 μmol/L) to drug-free con-
trol plasma, were used to establish the calibration curve. Four spiked 
plasma samples with known concentrations of MTX and 7-OHMTX 
and four diluted patient samples were used as quality control sam-
ples. Samples were prepared by adding 30 μL methanol containing 
10.9 μmol/L internal standard to 200 μL of patient sample, standard 
or control sample, vortexing and centrifugation at 16,100 g for 10 min 
at 4 °C. The supernatant was transferred into autosampler vials, 
which were stored in the cooled sample stack at 10 °C until analysis. 
Ten micro liter of each sample were injected into the system: blank 
samples were included after samples with high MTX concentrations.
The HPLC system consisted of a Transcend TLX-1 HTLC 
online extraction system with two Accela 600 pumps, an HTC PAL 
 autosampler and a valve interface module with built-in switching 
valves, all controlled by Aria (version 1.6.2) software (all from Thermo 
Fisher Scientific, MA, USA). A Cyclone column (50 × 0.5 mm, 50 μm 
particle size) was used for turbulent flow chromatography online 
extraction, and analytical separation was achieved on an Uptisphere 
C18 column (125 × 2.1 mm, 5 μm particle size). Chromatography was 
performed at room temperature (approx. 24 °C), and the LC flow was 
diverted into waste between 0 and 4 min and 7 and 10 min, using a 
divert valve. The LC method is summarized in Supplementary Table 1.
Mass spectrometric analysis was performed on a Q Exactive 
hybrid instrument controlled by Tune (version 2.2 SP1) and XCali-
bur (version 2.2 SP 1.48) software (all from Thermo Fisher Scientific, 
MA, USA). As the ionization interface, heated electro spray ioniza-
tion (HESI) was used with the following parameters: sheath gas 70 
arbitrary units (AU), auxiliary gas 20 AU, sweep gas 5 AU and spray 
voltage 5 kV. The capillary and heater temperatures were maintained 
at 270 °C and 320 °C, respectively. Detection was done in the positive 
full-scan mode with a resolution of 70,000 full width at half maxi-
mum (calculated for m/z 200). For quantification, extracted ion chro-
matograms with a window of 10 ppm of the singly charged pseudo 
molecular ions [M+H]+ were used. The following calculated exact 
masses were used: m/z 455.17859 for MTX, m/z 471.17351 for 7-OHMTX 
and m/z 458.19742 for the internal standard MTX-d3.
To validate the performance of the LC-MS method, quality con-
trol samples and diluted patient samples were analyzed six times on 
the same day to calculate within-day inaccuracy and imprecision 
and on six different days to calculate between-day inaccuracy and 
imprecision. To estimate the limit of quantitation, the imprecision at 
the lowest standard (0.01 μmol/L), which is ten times lower than the 
concentration at which leucovorin treatment should be stopped, was 
determined (10 measurements on 3 days).
Matrix effects were evaluated using the post-column infusion 
method, as described by Bonfiglio et  al. [6]. A solution containing 
MTX, 7-OHMTX and MTX-d3, at concentrations of 0.96, 0.92 and 
1.42 μmol/L, respectively, was infused into the column effluent at a 
flow rate of 10 μL/min. Concurrently, eight samples, including hemo-
lytic, icteric and lipemic samples, were prepared as described above, 
but without internal standard in the precipitation solution, and the 
resulting chromatograms were examined for regions showing ion 
suppression or enhancement.
Samples (four quality control samples and 2 patient samples) were 
left at room temperature for 2 days (exposed to or protected from light) 
to evaluate sample stability. The stability of samples after preparation 
was tested by re-injecting previously prepared controls and patient 
samples that were stored in the cooled autosampler stack at 10 °C for 2 
days. Additionally, freshly prepared quality control  samples and three 
fresh patient samples were subjected to three freeze/thaw cycles.
Immunoassays
Methotrexate concentrations were determined by a fluorescence 
polarization immunoassay (TDx/TDxFLx Methotrexate II, Abbott 
Laboratories), chemiluminescence microparticle immunoassay 
(Architect Methotrexate, Abbott Laboratories) and a homogeneous 
enzymatic immunoassay (ARK™ methotrexate assay, ARK Diagnos-
tics) on Cobas® c502 (Roche Diagnostics). Performance characteristics 
of these assays, as reported in the package inserts, are summarized 
in Table 1. Processing and storage of reagents, calibrators and control 
materials, operation of the instruments and all measurements were 
performed according to the manufacturers’ instructions. During the 
evaluation, reagents, calibrators and control materials from single 
production batches were used.
Samples were equilibrated to 18–25 °C and mixed gently prior to 
measurement. The performance of each instrument was assessed by 
running quality control samples before patient samples in each assay 
run. Samples exceeding the standard range were diluted according to 
the manufacturers’ protocols: for the Architect assay, the extended 
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range control samples provided by the manufacturer were processed 
in parallel to ensure the accuracy of sample dilution.
Sample sources and handling
Residual heparin plasma samples (n = 153) were collected follow-
ing routine measurement with the TDX assay and stored at –20 °C. 
Samples with extensive hemolysis, lipemia or bilirubinemia were 
excluded from the analysis. All samples were thawed, aliquoted and 
stored at –20 °C until analysis with each of the four assay systems. 
Repeated measurements of MTX levels with the TDX assay showed 
that MTX concentrations were stable over 12 months when stored at 
–20 °C, with two freeze-thaw cycles (data not shown). The reuse of 
remnant samples was approved by the local Zürich Cantonal Ethical 
Committee.
Imprecision and accuracy
Assay imprecision was determined according to the Clinical and Lab-
oratory Standards Institute (CLSI) EP15-A3 guideline [7]. Imprecision 
was assessed using three levels of the manufacturers’ control materi-
als within the relevant calibration range and plasma samples diluted 
with blank plasma from a healthy subject to three concentrations 
ranging between 0.02 and 1 μmol/L. Measurements were performed 
over 5 days, with one run per day and five replicates per run. The 
Architect assay kit includes three high-level controls, which exceed 
the measurement range and require manual dilution. As manual 
dilution may introduce an additional source of error, which does not 
reflect the instrument performance, we did not include these controls 
in the assessment of precision. However, they were included when-
ever dilution of patient samples was necessary (see above). Accuracy 
was determined from the reported concentrations of the quality con-
trol samples and by comparison with LC-MS measurements.
Linearity
The reported linearity was verified according to the National 
 Committee on Clinical Laboratory Standards (NCCLS) guideline 
EP6-A [8], using a dilution series of six concentrations within the 
calibration range of each immunoassay (Table 1). Dilutions were 
prepared with two plasma pools spiked with low or high concentra-
tions of MTX, and measurements were performed in duplicate within 
a single run. Polynomial regression analysis was performed for the 
first-, second- and third-order polynomials. Acceptance criteria were 
non-significance (p > 0.05) of the nonlinear coefficients or, if a statisti-
cally significant non-linearity was detected, a deviation from linear-
ity lower than the manufacturer’s claim for imprecision.
Limit of quantitation (LOQ)
The sensitivity claimed by the manufacturer was verified using four 
different spiked plasma samples at the reported LOQ (0.04 μmol/L). 
Each sample was measured in triplicate in three runs according to 
the CLSI EP17-A2 guideline [9], resulting in a total of 36 measure-
ments at the claimed LOQ.
Method comparison
Residual heparinized plasma samples were analyzed with the TDX, 
Architect, ARK immunoassay and LC-MS, with one replicate each.
Statistical analyses
Agreement between methods was estimated using Passing Bablok 
regression analysis [10], Bland-Altman difference plots [11] and Pear-
son’s correlation coefficient: samples below the LOQ of the immuno-
assays were excluded from the statistical analyses. All calculations 
were determined using Analyse-it software (Analyse-it Software) on 
Microsoft Excel 14.0 (Microsoft).
Results
LC-MS method
The calibration curve was stable throughout the evaluation 
period and was linear over an MTX concentration range of 
Table 1: Assay specifications according to package inserts. 
  TDx/TDxFLx methotrexate II   Architect methotrexate   ARK™ MTX immunoassay
Method   Fluorescence polarization 
immunoassay (FPIA)
  Chemiluminescence microparticle 
immunoassay (CMIA)
  Homogeneous enzyme 
immunoassay
Measuring range   0.02–1.0 μmol/L   0.04–1.5 μmol/L   0.04–1.2 μmol/L
LOQ   Not specified   0.04 μmol/L   0.04 μmol/L
Assay duration   Not measured   18 min   10 min
Cross reactivities      
7-OHMTX   0%   0%   None (  ≤  0.07%)
DAMPA   26%/59%a   46%/83%b   64.3%/100%c
aMTX 5 μmol/L, DAMPA 5 μmol/L or 1000 μmol/L; bMTX 0.05 μmol/L or 1 μmol/L, DAMPA 5 μmol/L; cMTX 0 μmol/L, DAMPA not specified.
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0.01–11.01 μmol/L. The coefficient of determination (R2), as 
an indicator of the goodness of fit of the calibration curve, 
was consistently above 0.998. By contrast, the curve was 
quadratic for 7-OHMTX over a concentration range of 0.01–
10.64 μmol/L, with a coefficient of determination  > 0.994. 
Bias and imprecision of the LC-MS method are summa-
rized in Table 2. The imprecision and bias at the lowest 
calibrator (0.01 μmol/L) was 2.5% and –0.2%, respectively. 
Analysis of eight blank samples showed no relevant matrix 
effect. MTX concentrations in control and patient samples 
were stable for 48  h at room temperature irrespectively 
if protected from light or not (accuracy 99%–105%) and 
samples after preparation were stable for at least 48 h in 
the cooled autosampler (accuracy 101%–105%). Accuracy 
after three freeze thaw cycles was between 97% and 101% 
for spiked control and patient samples.
Imprecision and accuracy
The within-run (repeatability), between-run and total 
(within-laboratory) imprecisions are summarized in 
Table 3. The Architect assay showed a total impreci-
sion  < 5.1%  and  < 6.3% for quality control materials and 
human plasma, respectively, consistent with the manu-
facturer’s claimed value of  < 7.5%. Total imprecision for 
Table 2: Imprecision and inaccuracy of the LC-MS method. 
Sample   L1  L2  L3  L4  HP1  HP2  HP3  HP4
Target, μmol/L   0.04  0.44  4.41  8.81  –  –  –  –
Mean, μmol/L                
 Within run (n = 6)   0.05  0.44  4.29  8.70  0.07  0.30  0.88  7.91
 Between run (n = 6)   0.05  0.45  4.34  8.81  0.08  0.30  0.89  7.91
Bias, %                
 Within run (n = 6)   4  –1  –3  –1  –  –  –  –
 Between run (n = 6)   6  1  –2  0  –  –  –  –
Imprecision, %                
 Within run (n = 6)   2.1  1.5  1.1  0.5  1.1  1.0  0.5  1.9
 Between run (n = 6)   1.0  0.8  1.6  1.6  2.0  1.7  1.4  0.6
L1–L4, Quality control level 1–4; HP1–HP4, diluted patient plasma samples.
Table 3: Imprecision and inaccuracy verification of the Architect and ARK MTX assay.  
Sample   Low  Med  High  HP1  HP2  HP3
Architect MTX
  Mean concentration, μmol/L   0.08  0.46  1.00  0.08  0.32  0.89
  Target concentration, μmol/L   0.07  0.45  1.00  0.08  0.30  0.89
  Bias, %   14  3  0  12  8  0
Imprecision, %a            
  Within laboratory (total precision)   5.1  3.0  2.5  6.3  5.0  3.8
  Repeatability (within run)   5.0  2.6  2.5  6.3  5.0  3.4
  Between run   1.1   1.5   0.4   0.0   0.0   1.7
ARK MTX
  Mean concentration, μmol/L   0.08  0.39  0.81  0.09  0.27  1.02
  Target concentration, μmol/L   0.07  0.40  0.80  0.08  0.30  0.89
  Bias, %   9  –3  1  20  –10  14
Imprecision, %a            
  Within laboratory (total precision)   9.5  2.1  5.0  6.0  2.3  6.5
  Repeatability (within run)   7.4  2.1  3.0  5.9  2.3  6.0
  Between run   5.9  0.0  4.1  1.2  0.0  2.7
Low, med, high: quality control material; HP1–HP3: diluted patient plasma samples (target value was determined by LC-MS). aImprecision claims 
of the manufacturers are for the Architect assay  < 7.5% total CV (all concentrations) and for the ARK assay   ≤  10% total CV for samples  > 0.1 μmol/L 
and a SD  ≤  0.01 for samples   ≤  0.1 μmol/L.
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the ARK assay was  < 9.5% for quality control materials 
and  < 6.5% for human plasma, compared with a claimed 
value of  < 10% (or a standard deviation of  < 0.01 μmol/L 
for values  < 1 μmol/L).
The accuracy of both the Abbott and the ARK assays 
was evaluated using quality control materials and human 
plasma samples at three concentrations each. Both assays 
showed higher bias at lower concentrations (Table 3). For 
the ARK assay, a positive drift of low control values was 
observed during the evaluation period, which necessi-
tated frequent re-calibration of the assay every 3–5 days. 
By contrast, the Abbott assay showed a stable perfor-
mance over 4.5 months study period.
Linearity
The Architect assay was shown to be linear over the given 
measurement range (0.04–1.5 μmol/L): none of the non-
linear coefficients of the second and third order polyno-
mials was significant (p > 0.05). The maximum difference 
was 3.4% between the linear and quadratic model and 
6.1% between the linear and the third order polynomial 
model (Supplementary Figure 1A and B).
For the ARK assay, the third order polynomial fit was 
significantly better than the linear fit, with a maximum 
difference of 0.017 μmol/L (48.1%) at the lowest concen-
tration (0.055 μmol/L) (Supplementary Figure 1C and D). 
This is higher than the manufacturer’s reported error of 
0.01 μmol/L at concentrations  < 0.1 μmol/L and is consist-
ent with the high bias of samples at the reported LOQ of 
0.04 μmol/L (see below).
Limit of quantitation
The LOQ of the Architect assay could be verified at the 
reported limit of 0.04 μmol/L using spiked plasma samples 
from four control donors (Table 4). All data were consist-
ent with the manufacturer’s claimed total error of  < 25%. 
For the ARK assay, total error at the LOQ is not stated 
in the package insert (the LOQ was defined as LOQ–2 
SD > LOD). All four samples had an acceptable coefficient 
of variation, of  < 18%, but a bias of up to 0.019 μmol/L was 
observed, resulting in a total error of up to 58% (Table 4).
Method comparison
The comparison of MTX levels measured by the Architect 
assay, compared with those measured by the TDX assay 
and the LC-MS method is shown in Figure 1. There were 
strong correlations between the Architect assay and the 
LC-MS and TDX assays, with a Pearson’s correlation coef-
ficient of 0.999 for both comparisons (Figure 1A and E). If 
only samples within the measuring range of the Architect 
assay were analyzed, the Pearson’s correlation coefficient 
was 0.996 and 0.995 for the LC-MS and TDX assay, respec-
tively (Figure 1B and F). Compared with the LC-MS method, 
the Architect assay showed a slight positive bias, with a 
slope of 1.08 [95% confidence interval (CI) 1.06–1.09] and 
an intercept of 0.02 (95% CI 0.01–0.02). The Bland-Altman 
plot revealed a positive bias of 12.2% at concentrations up 
to 500 μmol/L (Figure 1C) and 14.7% for concentrations 
below 1.5 μmol/L (Figure 1D). The Architect and the TDX 
assay showed a good agreement in the Passing-Bablok 
analysis (slope 1.00, 95% CI 0.98–1.03; intercept 0.00, 95% 
CI 0.00–0.01; Figure 1E) and in the Bland-Altman plot 
(mean difference 1.3%, Figure 1G).
There was also a highly significant correlation 
between the ARK assay and LC-MS, with Pearson’s cor-
relation coefficients of 0.999 overall (Figure 2A) and 0.990 
for samples within the calibration range (Figure 2B). For 
all samples up to 500 μmol/L, the ARK assay showed 
good agreement with LC-MS in Passing-Bablok regres-
sion analysis, with a slope of 1.00 (95% CI 0.97–1.02) 
and an intercept of 0.04 (95% CI 0.04–0.06). However, 
the Bland-Altman plot revealed a mean positive bias of 
20.5%, which decreased to 8.6% and 1.1% when only 
samples above 0.2 μmol/L and 1.2 μmol/L, respectively, 
were compared (data not shown). For samples within 
the calibration range (up to 1.2 μmol/L), the mean posi-
tive bias was 33.5%, and this figure increased for samples 
below 0.2  μmol/L (Figure  2D). Furthermore, compared 
with the previous TDX assay, there was a positive bias 
of 7.1% in the Bland-Altman analysis (Figure 2G), which 
was more pronounced for samples within the calibration 
range (Figure 2H). There was a highly significant corre-
lation between the two methods (Pearson’s correlation 
coefficient 1.000, Figure 2E), but Passing-Bablok regres-
sion analysis revealed a negative bias for samples with 
high MTX concentrations and a positive bias for samples 
within the calibration range (Figure 2E and F).
We also measured 7-OHMTX concentrations by LC-MS 
in 105 patient samples. For both assays we could not detect 
any strong correlation between the overestimation of MTX 
concentrations by the immunoassays and the 7-OHMTX 
concentration (data not shown). Significant cross-reactiv-
ity to the MTX metabolite 7-OHMTX has been reported for 
an enzyme-multiplied immunoassay [4].
Discrepant results were obtained with the four 
methods for three samples, which were taken from the 
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Figure 1: Method comparison with Passing-Bablok regression and Bland-Altman analysis of the Architect MTX assay vs. LC-MS (A–D) and 
the TDX MTX assay (E–H).
Left side: comparison of all samples measured, right side: comparison of samples within the calibration range of the Architect MTX assay.
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same patient on three consecutive days. On examining 
the clinical records, it was found that the patient had 
been treated with glucarpidase. The product of glucarpi-
dase action, DAMPA, shows high cross-reactivity with all 
three immunoassays (Table 1) and measurement of such 
samples is not recommended by the manufacturers. Over-
estimation of MTX concentration was highest for the ARK 
assay (up to 140-fold) and up to 80-fold for the Architect 
and TDX assay (data not shown). However, in the Archi-
tect package insert it is noted, that 48  h after glucarpi-
dase treatment patient samples can be measured with the 
assay, but we still found a 40-fold overestimation of MTX 
levels by the Architect assay in the 48 h sample.
Discussion
In this study we assessed the analytical performance of 
two immunological assays for the determination of MTX in 
human plasma samples and compared it with the former 
Abbott TDx/TDxFLx fluorescence polarization immunoas-
say and the LC-MS method. Imprecision of the Architect 
and ARK immunoassay was determined with the respec-
tive control materials and patient samples at three dilution 
levels. For both assays, imprecision was lower than the 
maximal values claimed in the package inserts: maximum 
imprecision for the lowest concentration sample was 6.3% 
for the Architect assay and 9.5% for the ARK assay.
We could confirm linearity up to 1.5 μmol/L and a 
LOQ of 0.04 μmol/L for the Architect assay. The ARK 
immunoassay was not linear over the specified calibra-
tion range; deviations from linearity were acceptable for 
concentrations  > 0.25 μmol/L, but the deviation was too 
high at lower concentrations. A bias could also be seen 
when we attempted to verify the LOQ: while imprecision 
at the reported LOQ (0.04 μmol/L) was acceptable ( < 18%) 
we observed a high positive bias of approximately 25%, 
resulting in a mean total error of 43%.
Correlations between the assays were evaluated using 
remnant patient samples. While Pearson’s correlation 
coefficients were consistently high, we observed a posi-
tive bias of the immunoassays, compared with the LC-MS 
method, as judged by Passing-Bablok regression and 
Bland-Altman plots. For the ARK assay, this bias was only 
evident at concentrations below 1.2 μmol/L (+33.5%), with 
a positive trend for samples close to the LOQ. The Archi-
tect assay showed a mean positive bias of +12.2% across 
all measured concentrations. Because leucovorin treat-
ment is usually stopped when MTX concentrations are 
between 0.05 and 0.2 μmol/L, overestimation of MTX con-
centrations below 0.2 μmol/L, as seen by the ARK assay, 
may lead to unnecessary prolongation of leucovorin 
treatment in patients treated with HDMTX. Our data are 
in agreement with the results of Godefroid et al. [12], who 
also observed a high total error at low concentrations with 
the ARK immunoassay running on Roche Cobas® c502, but 
not on Architect ci8200. We do not know if similar prob-
lems exist in other laboratories, or whether adjustments 
of the instrument or assay settings that are not currently 
offered by the manufacturers could eliminate this error.
Both the Architect and the ARK immunoassay require 
a three-step manual dilution of samples above the cali-
bration range to cover the wide range of plasma MTX 
concentrations encountered during HDMTX therapy. The 
manual dilution protocol is time-consuming and therefore 
delays the processing of samples for which the reporting 
of results might be time-critical, and is also a possible 
source of error. A fully automated dilution, as used in the 
TDX assay, is desirable for future applications. At present, 
a decision has to be made whether to dilute all samples 
and accept the higher time and reagent costs, or to dilute 
Table 4: Verification of the LOQ of the Architect and ARK MTX assay. 
Sample    Architect MTX   ARK MTX
S1  S2  S3  S4 S1  S2  S3  S4
Target value, μmol/L   0.041  0.039  0.039  0.042  0.041  0.039  0.039  0.042
Mean, μmol/L   0.043  0.042  0.040  0.043  0.059  0.044  0.049  0.048
SD, μmol/L   0.002  0.002  0.002  0.002  0.004  0.008  0.004  0.005
CV, %   4.5  4.9  5.0  4.8  6.7  18.0  8.5  10.3
Bias, μmol/L   0.003  0.003  0.001  0.001  0.019  0.005  0.010  0.006
Bias, %   7.0  7.1  3.7  2.8  46.8  13.7  24.5  15.4
Total error, %   14.4  15.2  11.9  10.8  57.9  43.3  38.5  32.3
Four different control plasma samples (S1–S4) were spiked with MTX to the reported LOQ (0.04 μmol/L). Nine aliquots of each sample were 
measured in triplicate on 3 days. The target value was determined by LC-MS. Total error was calculated as |bias|+1.65SD.
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Figure 2: Method comparison with Passing-Bablok regression and Bland-Altman analysis of the ARK MTX assay vs. LC-MS (A–D) and the 
TDX MTX assay (E–H).
Left side: comparison of all samples measured, right side: comparison of samples within the calibration range of the ARK MTX assay.
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only those samples that are above the calibration range 
(approx. 30% of all samples in our laboratory) and accept 
the resulting higher turnaround time.
Three samples showed significant differences in MTX 
levels between the three immunoassays and the LC-MS 
method. These samples originated from a patient who 
received glucarpidase treatment, resulting in the accumu-
lation of high levels of the MTX metabolite DAMPA. LC-MS 
analyses revealed significantly lower MTX levels in these 
samples, compared with the immunoassays, which sug-
gests that only a highly specific technique such as LC-MS 
is suitable for the measurement of MTX in patients treated 
with glucarpidase.
In conclusion, the Architect assay showed satisfactory 
performance, which fulfilled all manufacturer claims. The 
assay was found to be very stable, requiring only a single 
calibration during 4.5  months study period, and there-
fore the assay performance is well suited for routine MTX 
measurement in clinical samples. By contrast, the ARK 
immunoassay running on Roche Cobas® 502 showed an 
inadequate performance in the measurement of low con-
centrated samples, in addition to the high assay instabil-
ity necessitating new calibrations every 3–5 days during 
the evaluation period. Considering the fact that a total of 
15 reactions are needed for calibration and controls, this 
has a high impact on the costs of each reported result. For 
these reasons, we have adopted the Architect assay for the 
routine measurement of plasma MTX in our laboratory.
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